Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of Y-6 sublingual tablets in acute ischemic stroke patients undergoing endovascular treatment
ChiCTR2400081678Phase 2Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cilostazol + dexborneol and cilostazol in ischemic stroke (5 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Proportion with modified Rankin Scale 0 to 1 at 90 ± 7 days after randomization. Started Mar 2024; status: recruiting.
02
Drugs
cilostazol + dexborneolcilostazol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2400081678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081678.